Publications

Publications pour l'équipe Oncostat

Titre Publication Type Publication year Auteur
[Proton therapy for head and neck cancers] journalArticle 2017 Blanchard, P.; Frank, S. J.
Letter on the article "The BIAL/Biotrial case of death of a human volunteer in the first-in-human study of BIA 10-2474: Are we missing the fundamentals?" journalArticle 2017 Hill, C.; Asselain, B.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials journalArticle 2017 Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F.
Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis journalArticle 2017 Chebib, R.; Verlingue, L.; Cozic, N.; Faron, M.; Burtin, P.; Boige, V.; Hollebecque, A.; Malka, D.
Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis journalArticle 2017 Blanchard, P.; Belkhir, F.; Temam, S.; El Khoury, C.; De Felice, F.; Casiraghi, O.; Patrikidou, A.; Mirghani, H.; Levy, A.; Even, C.; Gorphe, P.; Nguyen, F.; Janot, F.; Tao, Y.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial journalArticle 2017 Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C.
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification journalArticle 2017 Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J.
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study journalArticle 2017 Atlan, P.; Bayar, M. A.; Lanoy, E.; Besse, B.; Planchard, D.; Ramon, J.; Raynard, B.; Antoun, S.
Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful? journalArticle 2017 Daroles, J.; Borget, I.; Suciu, V.; Mazouni, C.; Delaloge, S.; Balleyguier, C.
Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis journalArticle 2017 Blanchard, P.; Belkhir, F.; Temam, S.; El Khoury, C.; De Felice, F.; Casiraghi, O.; Patrikidou, A.; Mirghani, H.; Levy, A.; Even, C.; Gorphe, P.; Nguyen, F.; Janot, F.; Tao, Y.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials journalArticle 2017 Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F.
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients journalArticle 2017 Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J. P.; Caramella, C.; Planchard, D.; de Montpreville, V.; Deutsch, E.; Levy, A.; Besse, B.; Le Pechoux, C.
Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow journalArticle 2017 Blanchard, P.; Menard, C.; Frank, S. J.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study journalArticle 2017 Bredart, A.; Bodson, S.; Le Tourneau, C.; Flahault, C.; Bonnetain, F.; Beaudeau, A.; Coquan, E.; Dolbeault, S.; Paoletti, X.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial journalArticle 2017 Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C.
Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data journalArticle 2017 Yin, Jun; Paoletti, Xavier; Sargent, Daniel J; Mandrekar, Sumithra J
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? journalArticle 2017 Blanchard, P.; Bossi, A.; Fizazi, K.
In Regard to Arthurs et al journalArticle 2017 Blanchard, P.; Garden, A. S.
The frequency of cancer in France: Most recent data and trends journalArticle 2017 Ribassin-Majed, L.; Le-Teuff, G.; Hill, C.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study journalArticle 2017 Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L.
Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice journalArticle 2017 Berdelou, A.; Borget, I.; Godbert, Y.; Nguyen, T.; Garcia, M. E.; Chougnet, C. N.; Ferru, A.; Buffet, C.; Chabre, O.; Huillard, O.; Leboulleux, S.; Schlumberger, M.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors journalArticle 2017 Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study journalArticle 2017 Bredart, A.; Bodson, S.; Le Tourneau, C.; Flahault, C.; Bonnetain, F.; Beaudeau, A.; Coquan, E.; Dolbeault, S.; Paoletti, X.
Radiation-induced neurocognitive dysfunction in head and neck cancer patients journalArticle 2017 De Felice, F.; Blanchard, P.
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? journalArticle 2017 Blanchard, P.; Bossi, A.; Fizazi, K.
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies journalArticle 2016 Postel-Vinay, S.; Aspeslagh, S.; Lanoy, E.; Robert, C.; Soria, J. C.; Marabelle, A.
Hypofractionation for prostate cancer: a word of caution journalArticle 2016 Bossi, A.; Blanchard, P.
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial journalArticle 2016 Loi, S.; Dafni, U.; Karlis, D.; Polydoropoulou, V.; Young, B. M.; Willis, S.; Long, B.; de Azambuja, E.; Sotiriou, C.; Viale, G.; Ruschoff, J.; Piccart, M. J.; Dowsett, M.; Michiels, S.; Leyland-Jones, B.
Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group journalArticle 2016 Foulon, S.; Brennan, B.; Gaspar, N.; Dirksen, U.; Jeys, L.; Cassoni, A.; Claude, L.; Seddon, B.; Marec-Berard, P.; Whelan, J.; Paulussen, M.; Streitbuerger, A.; Oberlin, O.; Juergens, H.; Grimer, R.; Le Deley, M. C.
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes journalArticle 2016 Sio, T. T.; Lin, H. K.; Shi, Q.; Gunn, G. B.; Cleeland, C. S.; Lee, J. J.; Hernandez, M.; Blanchard, P.; Thaker, N. G.; Phan, J.; Rosenthal, D. I.; Garden, A. S.; Morrison, W. H.; Fuller, C. D.; Mendoza, T. R.; Mohan, R.; Wang, X. S.; Frank, S. J.
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials journalArticle 2016 Le Tourneau, C.; Kamal, M.; Tsimberidou, A. M.; Bedard, P.; Pierron, G.; Callens, C.; Rouleau, E.; Vincent-Salomon, A.; Servant, N.; Alt, M.; Rouzier, R.; Paoletti, X.; Delattre, O.; Bieche, I.
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial journalArticle 2016 Ribrag, V.; Koscielny, S.; Bosq, J.; Leguay, T.; Casasnovas, O.; Fornecker, L. M.; Recher, C.; Ghesquieres, H.; Morschhauser, F.; Girault, S.; Le Gouill, S.; Ojeda-Uribe, M.; Mariette, C.; Cornillon, J.; Cartron, G.; Verge, V.; Chassagne-Clement, C.; Dombret, H.; Coiffier, B.; Lamy, T.; Tilly, H.; Salles, G.
Statistical evaluation of surrogate endpoints with examples from cancer clinical trials journalArticle 2016 Buyse, M.; Molenberghs, G.; Paoletti, X.; Oba, K.; Alonso, A.; Van der Elst, W.; Burzykowski, T.
[Radiotherapy for nasopharyngeal carcinoma] journalArticle 2016 Maingon, P.; Blanchard, P.; Bidault, F.; Calmels, L.
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours journalArticle 2016 Gizzi, M.; Oberic, L.; Massard, C.; Poterie, A.; Gwenael, L. T.; Loriot, Y.; Albiges, L.; Baciarello, G.; Michels, J.; Bossi, A.; Blanchard, P.; Escudier, B.; Fizazi, K.
Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer journalArticle 2016 McKeever, M. R.; Sio, T. T.; Gunn, G. B.; Holliday, E. B.; Blanchard, P.; Kies, M. S.; Weber, R. S.; Frank, S. J.